Results 141 to 147 of about 16,388 (147)

T-cell-expressed proprotein convertase FURIN inhibits DMBA/TPA-induced skin cancer development

OncoImmunology, 2016
Maria Vähätupa, Zuzet Martinez Córdova, Ulrike May   +2 more
exaly  

Association of baseline LDL-C with total and cardiovascular mortality in patients using proprotein convertase subtilisin-kexin type 9 inhibitors: A systematic review and meta-analysis

Journal of Clinical Lipidology, 2019
Safi U Khan, Haris Riaz, Hammad Rahman
exaly  

Defective Neuropeptide Processing and Ischemic Brain Injury: A Study on Proprotein Convertase 2 and its Substrate Neuropeptide in Ischemic Brains

Journal of Cerebral Blood Flow and Metabolism, 2009
Shuqin Zhan, Giuseppe Pignataro, An Zhou   +2 more
exaly  

Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis

Postgraduate Medicine, 2015
Michael J Koren, Eli M Roth, James M Mckenney   +2 more
exaly  

Circulating proprotein convertase subtilisin-kexin type 9, all-cause mortality, and cardiovascular mortality: The Ludwigshafen Risk and Cardiovascular Health study

European Journal of Preventive Cardiology, 2017
GÜNTHER Silbernagel, Hubert Scharnagl, Marcus E Kléber   +2 more
exaly  

Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure–function relation to therapeutic inhibition

Nutrition, Metabolism and Cardiovascular Diseases, 2011
G Tibolla, Giuseppe Danilo Norata, Alberico L Catapano   +2 more
exaly  

Proprotein convertase subtilisin/kexin type 9 levels and aortic valve calcification: A prospective, cross sectional study

Journal of International Medical Research, 2016
exaly